Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117


Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.


The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D'Andrea RJ, Maciejewski JP, Scott HS, Hahn CN, Hiwase DK.

Leukemia. 2019 May 14. doi: 10.1038/s41375-019-0479-8. [Epub ahead of print]


Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.

Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S.

Blood. 2019 Jul 4;134(1):85-89. doi: 10.1182/blood.2019000120. Epub 2019 Apr 9. No abstract available.


Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.

Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong ASM.

Br J Haematol. 2019 Aug;186(3):e56-e60. doi: 10.1111/bjh.15894. Epub 2019 Mar 27. No abstract available.


De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.

Magistroni V, Mauri M, D'Aliberti D, Mezzatesta C, Crespiatico I, Nava M, Fontana D, Sharma N, Parker W, Schreiber A, Yeung D, Pirola A, Readelli S, Massimino L, Wang P, Khandelwal P, Citterio S, Viltadi M, Bombelli S, Rigolio R, Perego R, Boultwood J, Morotti A, Saglio G, Kim DW, Branford S, Gambacorti-Passerini C, Piazza R.

Haematologica. 2019 Sep;104(9):1789-1797. doi: 10.3324/haematol.2017.179937. Epub 2019 Feb 28.


Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.

Shanmuganathan N, Branford S, Hughes TP, Hiwase D.

Blood Adv. 2019 Feb 12;3(3):370-374. doi: 10.1182/bloodadvances.2018027516. No abstract available.


The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.

Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A.

Leuk Lymphoma. 2019 Jul;60(7):1796-1802. doi: 10.1080/10428194.2018.1551533. Epub 2019 Jan 11.


Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.


BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.

Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.

Haematologica. 2018 Dec;103(12):2026-2032. doi: 10.3324/haematol.2018.189787. Epub 2018 Jul 5.


Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Geoghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, Stangl D, Donaldson Z, Altamura H, Georgievski J, Braley J, Brown A, Hahn C, Walker I, Kim SH, Choi SY, Park SH, Kim DW, White DL, Yong ASM, Ross DM, Scott HS, Schreiber AW, Hughes TP.

Blood. 2018 Aug 30;132(9):948-961. doi: 10.1182/blood-2018-02-832253. Epub 2018 Jul 2.


The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.

Eadie LN, Saunders VA, Branford S, White DL, Hughes TP.

Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.


Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.

Hiwase D, Tan P, D'Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, Hughes T.

Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21.


ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure.

Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangl D, Wang PPS, Price DJ, Tuke J, Schreiber AW, Scott HS, Hughes TP, Branford S.

Blood Adv. 2017 Jul 31;1(18):1369-1381. doi: 10.1182/bloodadvances.2017006825. eCollection 2017 Aug 8.


CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.


Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.


A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

Casolari DA, Nguyen T, Butcher CM, Iarossi DG, Hahn CN, Bray SC, Neufing P, Parker WT, Feng J, Maung KZY, Wee A, Vidovic L, Kok CH, Bardy PG, Branford S, Lewis ID, Lane SW, Scott HS, Ross DM, D'Andrea RJ.

Sci Rep. 2017 May 26;7(1):2467. doi: 10.1038/s41598-017-02655-7.


The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.

Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross DM, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen NJ, Sellers WR.

Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.


Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.


Molecular monitoring in chronic myeloid leukemia-how low can you go?

Branford S.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):156-163. Review.


Monitoring and defining early response: Where to draw the line?

Branford S.

Best Pract Res Clin Haematol. 2016 Sep;29(3):284-294. doi: 10.1016/j.beha.2016.10.006. Epub 2016 Oct 20. Review.


Current developments in molecular monitoring in chronic myeloid leukemia.

Marum JE, Branford S.

Ther Adv Hematol. 2016 Oct;7(5):237-251. Epub 2016 Jul 15. Review.


Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.

Yoshida C, Nakamae H, Fletcher L, Koga D, Sogabe T, Matsumura I, Kanakura Y, Branford S, Naoe T.

Springerplus. 2016 May 10;5:569. doi: 10.1186/s40064-016-2258-6. eCollection 2016.


BAM-matcher: a tool for rapid NGS sample matching.

Wang PP, Parker WT, Branford S, Schreiber AW.

Bioinformatics. 2016 Sep 1;32(17):2699-701. doi: 10.1093/bioinformatics/btw239. Epub 2016 May 3.


Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.


Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots.

Sala Torra O, Beppu L, Smith JL, Welden L, Georgievski J, Gupta K, Kumar R, Yeung CC, Paguirigan A, Gooley TA, Branford S, Radich JP.

Blood. 2016 Jun 2;127(22):2773-4. doi: 10.1182/blood-2015-12-689059. Epub 2016 Apr 13. No abstract available.


BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.

Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA.

J Clin Pathol. 2016 Sep;69(9):817-21. doi: 10.1136/jclinpath-2015-203538. Epub 2016 Feb 2.


The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14.


Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.


Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene.

Ross DM, Altamura HK, Hahn CN, Nicola M, Yeoman AL, Holloway MR, Geoghegan J, Feng J, Schreiber AW, Branford S, Moore S, Scott HS.

Leukemia. 2016 Jun;30(6):1402-5. doi: 10.1038/leu.2015.301. Epub 2015 Oct 27. No abstract available.


KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong AS.

Blood. 2015 Dec 17;126(25):2720-3. doi: 10.1182/blood-2015-07-655589. Epub 2015 Oct 23.


Bantu expansion shows that habitat alters the route and pace of human dispersals.

Grollemund R, Branford S, Bostoen K, Meade A, Venditti C, Pagel M.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13296-301. doi: 10.1073/pnas.1503793112. Epub 2015 Sep 14.


A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system.

Enjeti A, Granter N, Ashraf A, Fletcher L, Branford S, Rowlings P, Dooley S.

Pathology. 2015 Oct;47(6):570-4. doi: 10.1097/PAT.0000000000000293.


A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia.

Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA.

J Mol Diagn. 2015 Mar;17(2):185-92. doi: 10.1016/j.jmoldx.2014.10.002. Epub 2014 Dec 29.


Detecting regular sound changes in linguistics as events of concerted evolution.

Hruschka DJ, Branford S, Smith ED, Wilkins J, Meade A, Pagel M, Bhattacharya T.

Curr Biol. 2015 Jan 5;25(1):1-9. doi: 10.1016/j.cub.2014.10.064. Epub 2014 Dec 18.


TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group.

Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17.


Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.

Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F.

Haematologica. 2014 Nov;99(11):1701-9. doi: 10.3324/haematol.2013.085977. Epub 2014 Sep 12.


Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan CG, Hughes TP, White DL.

Leukemia. 2015 Jan;29(1):230-2. doi: 10.1038/leu.2014.256. Epub 2014 Sep 2. No abstract available.


Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S.

Blood. 2014 Jul 3;124(1):153-5. doi: 10.1182/blood-2014-05-573485. No abstract available.


Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.

Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B.

Blood. 2014 Jul 31;124(5):729-36. doi: 10.1182/blood-2013-12-544015. Epub 2014 Jun 19.


Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP.

Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23.


Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.

Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F.

Int J Hematol. 2014;99(5):616-24.


Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP.

Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23. Review.


What challenges remain in chronic myeloid leukemia research?

Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM.

Haematologica. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381. No abstract available.


A comparative analysis of algorithms for somatic SNV detection in cancer.

Roberts ND, Kortschak RD, Parker WT, Schreiber AW, Branford S, Scott HS, Glonek G, Adelson DL.

Bioinformatics. 2013 Sep 15;29(18):2223-30. doi: 10.1093/bioinformatics/btt375. Epub 2013 Jul 9.


BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.

Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S.

Br J Cancer. 2013 Sep 17;109(6):1593-8. doi: 10.1038/bjc.2013.318. Epub 2013 Jun 25.


Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP.

Blood. 2013 Jul 25;122(4):515-22. doi: 10.1182/blood-2013-02-483750. Epub 2013 May 23.


Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP.

BMC Cancer. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173.


Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP.

Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20.


Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E.

Clin Chem. 2013 Jun;59(6):938-48. doi: 10.1373/clinchem.2012.196477. Epub 2013 Mar 7.


Continued therapeutic response monitoring in optimal responders with CML.

Branford S.

Clin Adv Hematol Oncol. 2012 Dec;10(12):819-21. Review. No abstract available.


Supplemental Content

Loading ...
Support Center